All In MedTech

FDA Clearance Tracker · P250029

SimpleScreen™ CRC

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this decision)Source: openFDAMethods & limitations

PMA

The decision

FDA number
P250029
Device name
SimpleScreen™ CRC
Applicant
Freenome, LLC
Applicant location
Brisbane, CA
Received
Aug 1, 2025
Decided
Jul 24, 2026
Decision
Approved
Supplements
2 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code PHP

FDA's approval statement

As written in FDA's record.

The SimpleScreen™ CRC test is a qualitative, in vitro diagnostic test intended to detect molecular signals associated with colorectal cancer. SimpleScreen CRC utilizes circulating cell-free DNA from plasma of peripheral whole blood collected in the SimpleScreen CRC blood collection kit.SimpleScreen CRC is indicated for colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease. Patients with a positive result should be followed by colonoscopy. SimpleScreen CRC is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code PHP. The earliest in FDA's data is P130017, decided Aug 11, 2014.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Freenome, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.